Search results for "Cancer"

showing 10 items of 11546 documents

I10 The anticancer activity of the antimalarial artesunate

2017

More than a decade ago, we initiated a research program on the molecular pharmacology of phytochemicals derived from Chinese medicinal herbs. A promising compound was artemisinin from Artemisia annua L. and its semisynthetic compound artesunate [1] . Artemisinin and artesunate are anti-malarial drugs. Our data indicated profound activity against cancer cells, but also against various viruses, Schistosoma, Trypanosoma, and even plant crown gall tumors. To elucidate the molecular mode of actions against cancer, we applied molecular biological and pharmacogenomic approaches in vitro and in vivo. Different signalling pathways were identified not only in cancer cells but also in cells infected w…

0301 basic medicineDrugmedia_common.quotation_subjectArtemisia annuaTraditional Chinese medicinePharmacologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineArtemisininmedia_commonPharmacologybiologybusiness.industryCancermedicine.diseasebiology.organism_classification030104 developmental biologychemistryArtesunate030220 oncology & carcinogenesisPharmacogenomicsCancer cellbusinessmedicine.drugBiochemical Pharmacology
researchProduct

Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.

2016

Treg cell-mediated immune suppression appears to represent a significant barrier to effective anticancer immune responses and their inactivation or removal is viewed as a potential therapeutic approach. Although suitable tools for selective Treg cell manipulation in man are missing, their number and function can be altered by a number of drugs and biologicals and by reprogramming tumor-infiltrating antigen presenting cells. Nanoparticles offer exceptional new options in drug and gene delivery by prolonging the circulation time of their cargo, protecting it from degradation and promoting its local accumulation in cells and tissues. In tumor therapy, the use of nanoparticles is expected to o…

0301 basic medicineDrugmedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Antigen-Presenting CellsBioengineeringDevelopmentBiologyGene deliveryT-Lymphocytes Regulatory03 medical and health sciences0302 clinical medicineImmune systemNeoplasmsAnimalsHumansGeneral Materials ScienceAntigen-presenting cellMelanomamedia_common030104 developmental biologyImmunologyDrug deliveryCancer researchNanomedicineNanoparticlesImmunotherapyReprogrammingFunction (biology)030215 immunologyNanomedicine (London, England)
researchProduct

Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.

2016

Drug attrition rates due to hepatotoxicity are an important safety issue considered in drug development. The HepG2 hepatoma cell line is currently being used for drug-induced hepatotoxicity evaluations, but its expression of drug-metabolizing enzymes is poor compared with hepatocytes. Different approaches have been proposed to upgrade HepG2 cells for more reliable drug-induced liver injury predictions. Areas covered: We describe the advantages and limitations of HepG2 cells transduced with adenoviral vectors that encode drug-metabolizing enzymes for safety risk assessments of bioactivable compounds. Adenoviral transduction facilitates efficient and controlled delivery of multiple drug-metab…

0301 basic medicineDrugmedia_common.quotation_subjectGenetic VectorsBiologyPharmacologyToxicologyENCODERisk AssessmentAdenoviridae03 medical and health sciencesToxicity TestsmedicineAnimalsHumansmedia_commonPharmacologyLiver injurychemistry.chemical_classificationReproducibility of ResultsGeneral MedicineHep G2 Cellsmedicine.disease030104 developmental biologyEnzymemedicine.anatomical_structureDrug developmentchemistryPharmaceutical PreparationsHepg2 cellsHepatocyteDrug DesignCancer researchHepatocytesChemical and Drug Induced Liver InjuryDrug metabolismExpert opinion on drug metabolismtoxicology
researchProduct

Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma

2016

The development of nucleic acid based vaccines against cancer has gained considerable momentum through the advancement of modern sequencing technologies and on novel RNA-based synthetic drug formats, which can be readily adapted following identification of every patient's tumor-specific mutations. Furthermore, affordable and individual ‘on demand’ production of molecularly optimized vaccines should allow their application in large groups of patients. This has resulted in the therapeutic concept of an active personalized cancer vaccine, which has been brought into clinical testing. Successful trials have been performed by intranodal administration of sterile isotonic solutions of synthetic …

0301 basic medicineDrugmedicine.medical_treatmentmedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyComputational biologyDevelopmentPharmacologyCancer VaccinesExcipients03 medical and health sciencesAntigens NeoplasmmedicineAnimalsHumansGeneral Materials ScienceRNA MessengerPrecision MedicineMelanomamedia_commonClinical Trials as TopicMessenger RNAbusiness.industryRNAImmunotherapy021001 nanoscience & nanotechnologyTumor antigenNanomedicine030104 developmental biologyLiposomesDrug deliveryNucleic acidNanoparticlesRNAImmunotherapyCancer vaccine0210 nano-technologybusinessNanomedicine
researchProduct

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.

2020

International audience; Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clin…

0301 basic medicineDual targeting[SDV]Life Sciences [q-bio]Cancer therapyKinasesAntineoplastic AgentsBioinformaticsBiochemistryAnticancer drugsSynergistic effectsHistone Deacetylases03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsReceptorsmedicineAnimalsHumansEpigeneticsPharmacologybiologybusiness.industryCancerDUAL (cognitive architecture)medicine.diseaseAnticancer drug3. Good healthEnzymesClinical trial[SDV] Life Sciences [q-bio]Histone Deacetylase Inhibitors030104 developmental biologyHistone030220 oncology & carcinogenesisbiology.proteinHistone deacetylases (HDACs)EpigeneticsDual inhibitorbusinessBiochemical pharmacology
researchProduct

Effect of colorectal cancer-derived extracellular vesicles on the immunophenotype and cytokine secretion profile of monocytes and macrophages.

2018

Abstract. Background Macrophages are one of the most important players in the tumor microenvironment. The polarization status of tumor associated macrophages into a pro-inflammatory type M1 or anti-inflammatory type M2 may influence cancer progression and patient survival. Extracellular vesicles (EVs) are membrane-bound vesicles containing different biomolecules that are involved in cell to cell signal transfer. Accumulating evidence suggests that cancer-derived EVs are taken up by macrophages and modulate their phenotype and cytokine profile. However, the interactions of cancer-derived EVs with monocytes and macrophages at various differentiation and polarization states are poorly understo…

0301 basic medicineDynaminsLipopolysaccharidesCell SurvivalCD14Macrophage polarizationLipopolysaccharide ReceptorsShort Reportlcsh:MedicineReceptors Cell Surfacecolorectal cancerBiochemistryMonocytesImmunophenotyping03 medical and health sciencesExtracellular VesiclesInterferon-gamma0302 clinical medicineCell Line TumormedicineCXCL10MacrophageHumansendocytosisSecretionLectins C-Typelcsh:QH573-671Molecular BiologyTumor microenvironmentlcsh:CytologyChemistryMonocyteMacrophageslcsh:RCell DifferentiationCell BiologyHLA-DR AntigenscytokinesCell biology030104 developmental biologymedicine.anatomical_structureMannose-Binding Lectins030220 oncology & carcinogenesisTetradecanoylphorbol AcetateCytokine secretionChemokinesColorectal NeoplasmsMannose ReceptorCell communication and signaling : CCS
researchProduct

Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

2021

The molecular pathways which promote lung cancer cell features have been broadly explored, leading to significant improvement in prognostic and diagnostic strategies. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have dramatically altered the treatment approach for patients with metastatic non-small cell lung cancer (NSCLC). Latest investigations by using next-generation sequencing (NGS) have shown that other oncogenic driver mutations, believed mutually exclusive for decades, could coexist in EGFR-mutated NSCLC patients. However, the exact clinical and pathological role of concomitant genomic aberrations needs to be investigated. In this systematic review, we ai…

0301 basic medicineEGFRNSCLC03 medical and health sciences0302 clinical medicinesystematic reviewPathologyRB1-214MedicineEpidermal growth factor receptorLung cancerPathologicalbiologybusiness.industrymedicine.diseaserespiratory tract diseasesconcurrent genomic alterationCritical appraisal030104 developmental biologyLung cancer cellconcurrent genomic alterationsNGS030220 oncology & carcinogenesisConcomitantCancer researchbiology.proteinNon small cellbusinessTyrosine kinase<i>EGFR</i>Journal of Molecular Pathology
researchProduct

Death Receptor 5 Displayed on Extracellular Vesicles Decreases TRAIL Sensitivity of Colon Cancer Cells

2020

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is considered to be a promising antitumor drug because of its selective proapoptotic properties on tumor cells. However, the clinical application of TRAIL is until now limited because of the resistance of several cancer cells, which can occur at various levels in the TRAIL signaling pathway. The role of decoy receptors that can side-track TRAIL, thereby preventing the formation of an activated death receptor, has been extensively studied. In this study, we have focused on extracellular vesicles (EVs) that are known to play a role in cell-to-cell communication and that can be released by donor cells into the medium transferring …

0301 basic medicineENDOCYTOSISTRAILSURFACE EXPRESSIONCell and Developmental Biology03 medical and health sciences0302 clinical medicineSecretionDR5Decoy receptorsReceptorlcsh:QH301-705.5Original Researchreceptor-ligand traffickingEXOSOMESChemistryapoptosisCell BiologyMicrovesiclesconditioned medium030104 developmental biologylcsh:Biology (General)Apoptosis030220 oncology & carcinogenesisCancer cellCancer researchTumor necrosis factor alphareceptor–ligand traffickingextracellular vesiclesDecoyDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients

2020

Background: Melatonin is a biomarker of the central circadian clock and its chronobiotic actions entraining circadian rhythms to the light-dark cycle are well known. Reduction in melatonin levels and altered circadian rhythms have been associated with a high risk of breast cancer. Melatonin has also shown to display anti-proliferative effects on breast cancer growth and proliferation. Evaluation of melatonin circadian rhythm alterations in patients bearing breast cancer may have interesting prognostic and therapeutic applications. Objective: To review studies evaluating the circadian rhythm of melatonin in breast cancer patients. The effects of surgery and chemotherapy on melatonin secreti…

0301 basic medicineEndocrinology Diabetes and MetabolismBreast surgerymedicine.medical_treatmentChronobioticCircadian clockEstrogen receptorPhysiologyBreast Neoplasms030209 endocrinology & metabolismHistory 21st CenturyAntioxidantsMelatonin03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansImmunology and AllergyCircadian rhythmMelatoninbusiness.industrymedicine.diseaseCircadian RhythmSleep Quality030104 developmental biologyQuality of LifeBiomarker (medicine)FemaleSleepbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugEndocrine, Metabolic &amp; Immune Disorders - Drug Targets
researchProduct

Metabolic classification and intervention opportunities for tumor energy dysfunction

2021

A comprehensive view of cell metabolism provides a new vision of cancer, conceptualized as tissue with cellular-altered metabolism and energetic dysfunction, which can shed light on pathophysiological mechanisms. Cancer is now considered a heterogeneous ecosystem, formed by tumor cells and the microenvironment, which is molecularly, phenotypically, and metabolically reprogrammable. A wealth of evidence confirms metabolic reprogramming activity as the minimum common denominator of cancer, grouping together a wide variety of aberrations that can affect any of the different metabolic pathways involved in cell physiology. This forms the basis for a new proposed classification of cancer accordin…

0301 basic medicineEndocrinology Diabetes and MetabolismMetabolic reprogrammingReviewBiologyBioinformaticsBiochemistryMicrobiology03 medical and health sciences0302 clinical medicinetumor reprogrammingmedicinetumor microenvironmentMolecular BiologyTumor ecosystemTumor reprogrammingTumor microenvironmentCancerCommon denominatorMetabolismHypoxia (medical)medicine.diseaseQR1-502Metabolic pathway030104 developmental biologyCell metabolismTumor microenvironment030220 oncology & carcinogenesistumor ecosystemmedicine.symptom
researchProduct